Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)

類似資料

• Time to progression to castration-resistant prostate cancer after commencing combined androgen blockade for advanced hormone-sensitive prostate cancer
  著者:: Tamada, Satoshi, 等
  出版事項: (2018)
• The difference in the survival rate of patients with metastatic renal cell carcinoma in the intermediate-risk group of the Memorial Sloan Kettering Cancer Center criteria
  著者:: Tamada, Satoshi, 等
  出版事項: (2018)
• Second-line treatment after sunitinib therapy in patients with renal cell carcinoma: a comparison of axitinib and mammalian target of rapamycin inhibitors
  著者:: Tamada, Satoshi, 等
  出版事項: (2018)
• Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade
  著者:: Yokomizo, Yumiko, 等
  出版事項: (2016)
• Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane Chemotherapy
  著者:: Shimizu, Yasuomi, 等
  出版事項: (2018)